AIRIS Crohn Registry. Assessing the Impact of RISankizumab on clinical outcomes and biomarkers in Crohns Disease.
OBSERVATIONAL STUDY WITH MEDICINES
Clinical trial information
- Promoter: Alejandro Otero Foundation for Biosanitary Research in Eastern Andalusia (FIBAO)
- Execution start: 07/06/24
- End of execution: 30/06/26
- IP: ANTONIO MARIA CABALLERO MATEOS
